The role of Hepassocin in the development of non-alcoholic fatty liver disease

Hung Tsung Wu, Feng Hwa Lu, Horng Yih Ou, Yu Chu Su, Hao Chang Hung, Jin Shang Wu, Yi Ching Yang, Chao Liang Wu, Chih Jen Chang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background & Aims While non-alcoholic fatty liver disease (NAFLD) is the most common risk factor of chronic liver disease, the mechanisms that initiate its development are obscure. Hepassocin (HPS) is a hepatokine that has been reported to be involved in liver regeneration. In addition to the mitogenic activity of HPS, HPS expression is decreased in patients with hepatoma. However, the role of HPS in NAFLD is still unknown. Methods A total of 393 subjects with (n = 194) or without (n = 199) NAFLD were enrolled to evaluate the serum HPS concentration. In order to clarify the causal inference between HPS and NAFLD, we used experimental animal and cell models. Hepatic overexpression or silencing of HPS was achieved by lentiviral vector delivery in mice and lipofectamine transfection in HepG2 cells. Lipogenesis related proteins were detected by Western blots. The expression of inflammatory factors was determined by real-time polymerase chain reaction. Results Subjects with NAFLD had a higher serum HPS concentration than those without it. Overexpression of HPS increased hepatic lipid accumulation and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat diet-induced hepatic steatosis and decreased NAS in mice. Additionally, oleic acid, a steatogenic reagent, increased HPS expression in hepatocytes. Furthermore, overexpression of HPS in HepG2 cells induced lipid accumulation through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway, whereas deletion of HPS decreased oleic acid-induced lipid accumulation. Conclusions The present study provides evidence that HPS plays an important role in NAFLD and induces hepatic lipid accumulation through an ERK1/2-dependent pathway.

Original languageEnglish
Pages (from-to)1065-1072
Number of pages8
JournalJournal of Hepatology
Volume59
Issue number5
DOIs
Publication statusPublished - Nov 1 2013
Externally publishedYes

Fingerprint

Lipids
Mitogen-Activated Protein Kinase 3
Liver
Mitogen-Activated Protein Kinase 1
Hep G2 Cells
Oleic Acid
Lipogenesis
Liver Regeneration
Non-alcoholic Fatty Liver Disease
High Fat Diet
Serum
Transfection
Liver Diseases
Real-Time Polymerase Chain Reaction
Hepatocytes
Hepatocellular Carcinoma
Chronic Disease
Animal Models
Western Blotting
Proteins

Keywords

  • Fatty acids
  • Hepatic steatosis
  • Liver
  • Oleic acid
  • STAT3

ASJC Scopus subject areas

  • Hepatology

Cite this

Wu, H. T., Lu, F. H., Ou, H. Y., Su, Y. C., Hung, H. C., Wu, J. S., ... Chang, C. J. (2013). The role of Hepassocin in the development of non-alcoholic fatty liver disease. Journal of Hepatology, 59(5), 1065-1072. https://doi.org/10.1016/j.jhep.2013.06.004

The role of Hepassocin in the development of non-alcoholic fatty liver disease. / Wu, Hung Tsung; Lu, Feng Hwa; Ou, Horng Yih; Su, Yu Chu; Hung, Hao Chang; Wu, Jin Shang; Yang, Yi Ching; Wu, Chao Liang; Chang, Chih Jen.

In: Journal of Hepatology, Vol. 59, No. 5, 01.11.2013, p. 1065-1072.

Research output: Contribution to journalArticle

Wu, HT, Lu, FH, Ou, HY, Su, YC, Hung, HC, Wu, JS, Yang, YC, Wu, CL & Chang, CJ 2013, 'The role of Hepassocin in the development of non-alcoholic fatty liver disease', Journal of Hepatology, vol. 59, no. 5, pp. 1065-1072. https://doi.org/10.1016/j.jhep.2013.06.004
Wu, Hung Tsung ; Lu, Feng Hwa ; Ou, Horng Yih ; Su, Yu Chu ; Hung, Hao Chang ; Wu, Jin Shang ; Yang, Yi Ching ; Wu, Chao Liang ; Chang, Chih Jen. / The role of Hepassocin in the development of non-alcoholic fatty liver disease. In: Journal of Hepatology. 2013 ; Vol. 59, No. 5. pp. 1065-1072.
@article{4fa570c04d174c0f86c188899685a355,
title = "The role of Hepassocin in the development of non-alcoholic fatty liver disease",
abstract = "Background & Aims While non-alcoholic fatty liver disease (NAFLD) is the most common risk factor of chronic liver disease, the mechanisms that initiate its development are obscure. Hepassocin (HPS) is a hepatokine that has been reported to be involved in liver regeneration. In addition to the mitogenic activity of HPS, HPS expression is decreased in patients with hepatoma. However, the role of HPS in NAFLD is still unknown. Methods A total of 393 subjects with (n = 194) or without (n = 199) NAFLD were enrolled to evaluate the serum HPS concentration. In order to clarify the causal inference between HPS and NAFLD, we used experimental animal and cell models. Hepatic overexpression or silencing of HPS was achieved by lentiviral vector delivery in mice and lipofectamine transfection in HepG2 cells. Lipogenesis related proteins were detected by Western blots. The expression of inflammatory factors was determined by real-time polymerase chain reaction. Results Subjects with NAFLD had a higher serum HPS concentration than those without it. Overexpression of HPS increased hepatic lipid accumulation and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat diet-induced hepatic steatosis and decreased NAS in mice. Additionally, oleic acid, a steatogenic reagent, increased HPS expression in hepatocytes. Furthermore, overexpression of HPS in HepG2 cells induced lipid accumulation through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway, whereas deletion of HPS decreased oleic acid-induced lipid accumulation. Conclusions The present study provides evidence that HPS plays an important role in NAFLD and induces hepatic lipid accumulation through an ERK1/2-dependent pathway.",
keywords = "Fatty acids, Hepatic steatosis, Liver, Oleic acid, STAT3",
author = "Wu, {Hung Tsung} and Lu, {Feng Hwa} and Ou, {Horng Yih} and Su, {Yu Chu} and Hung, {Hao Chang} and Wu, {Jin Shang} and Yang, {Yi Ching} and Wu, {Chao Liang} and Chang, {Chih Jen}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.jhep.2013.06.004",
language = "English",
volume = "59",
pages = "1065--1072",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The role of Hepassocin in the development of non-alcoholic fatty liver disease

AU - Wu, Hung Tsung

AU - Lu, Feng Hwa

AU - Ou, Horng Yih

AU - Su, Yu Chu

AU - Hung, Hao Chang

AU - Wu, Jin Shang

AU - Yang, Yi Ching

AU - Wu, Chao Liang

AU - Chang, Chih Jen

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Background & Aims While non-alcoholic fatty liver disease (NAFLD) is the most common risk factor of chronic liver disease, the mechanisms that initiate its development are obscure. Hepassocin (HPS) is a hepatokine that has been reported to be involved in liver regeneration. In addition to the mitogenic activity of HPS, HPS expression is decreased in patients with hepatoma. However, the role of HPS in NAFLD is still unknown. Methods A total of 393 subjects with (n = 194) or without (n = 199) NAFLD were enrolled to evaluate the serum HPS concentration. In order to clarify the causal inference between HPS and NAFLD, we used experimental animal and cell models. Hepatic overexpression or silencing of HPS was achieved by lentiviral vector delivery in mice and lipofectamine transfection in HepG2 cells. Lipogenesis related proteins were detected by Western blots. The expression of inflammatory factors was determined by real-time polymerase chain reaction. Results Subjects with NAFLD had a higher serum HPS concentration than those without it. Overexpression of HPS increased hepatic lipid accumulation and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat diet-induced hepatic steatosis and decreased NAS in mice. Additionally, oleic acid, a steatogenic reagent, increased HPS expression in hepatocytes. Furthermore, overexpression of HPS in HepG2 cells induced lipid accumulation through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway, whereas deletion of HPS decreased oleic acid-induced lipid accumulation. Conclusions The present study provides evidence that HPS plays an important role in NAFLD and induces hepatic lipid accumulation through an ERK1/2-dependent pathway.

AB - Background & Aims While non-alcoholic fatty liver disease (NAFLD) is the most common risk factor of chronic liver disease, the mechanisms that initiate its development are obscure. Hepassocin (HPS) is a hepatokine that has been reported to be involved in liver regeneration. In addition to the mitogenic activity of HPS, HPS expression is decreased in patients with hepatoma. However, the role of HPS in NAFLD is still unknown. Methods A total of 393 subjects with (n = 194) or without (n = 199) NAFLD were enrolled to evaluate the serum HPS concentration. In order to clarify the causal inference between HPS and NAFLD, we used experimental animal and cell models. Hepatic overexpression or silencing of HPS was achieved by lentiviral vector delivery in mice and lipofectamine transfection in HepG2 cells. Lipogenesis related proteins were detected by Western blots. The expression of inflammatory factors was determined by real-time polymerase chain reaction. Results Subjects with NAFLD had a higher serum HPS concentration than those without it. Overexpression of HPS increased hepatic lipid accumulation and NAFLD activity scores (NAS), whereas deletion of HPS improved high fat diet-induced hepatic steatosis and decreased NAS in mice. Additionally, oleic acid, a steatogenic reagent, increased HPS expression in hepatocytes. Furthermore, overexpression of HPS in HepG2 cells induced lipid accumulation through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway, whereas deletion of HPS decreased oleic acid-induced lipid accumulation. Conclusions The present study provides evidence that HPS plays an important role in NAFLD and induces hepatic lipid accumulation through an ERK1/2-dependent pathway.

KW - Fatty acids

KW - Hepatic steatosis

KW - Liver

KW - Oleic acid

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84885950639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885950639&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2013.06.004

DO - 10.1016/j.jhep.2013.06.004

M3 - Article

C2 - 23792031

AN - SCOPUS:84885950639

VL - 59

SP - 1065

EP - 1072

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -